Why Branded Pharmaceuticals Still Command a Market Despite Generic Growth

The rise of generic medicine use is one of the defining trends in global pharmaceutical markets — driven by healthcare cost pressures, formulary management by payers and governments, and the growing body of evidence supporting generic bioequivalence. Yet branded pharmaceutical products — including branded generics — continue to hold significant market positions in India and across international markets.

Understanding why helps wholesalers and importers make informed decisions about which product category to source and for which markets.

---

Prescriber Habit and Brand Recognition

In markets where physicians prescribe by brand name (rather than INN), prescriber preference creates demand that is not easily dislodged by a cheaper generic equivalent. This is particularly true in:

- India's private healthcare sector: Branded prescribing is the dominant model in India's large private hospital and clinic sector, where pharmaceutical company marketing relationships with prescribers are well-established - Premium market segments globally: In markets where patients or payers prefer or require branded products (whether originator brands or well-known branded generics), the brand premium is commercially viable

Brand recognition operates at multiple levels — doctor familiarity, patient trust, and pharmacist preference all contribute to sustained branded demand even when generic alternatives exist.

---

Patent Protection and Originator Monopolies

For on-patent pharmaceutical products — those within their patent exclusivity and data exclusivity period — no generic is legally available. The originator brand has monopoly supply during this period, which can last 10–20 years from original filing.

For Indian pharmaceutical traders, on-patent originator brands are a legitimate product category — traders can source and distribute originator brands through authorised supply channels. These products have a defined market where substitution is not legally available.

---

Branded Generics: India's Distinctive Market Structure

India has an unusually large segment of branded generics — products where off-patent molecules are sold under manufacturer proprietary brand names, rather than by INN. This is distinct from both originator brands (on-patent) and purely INN-named generics.

Examples: An Indian manufacturer produces Amoxicillin 500mg capsules under their own brand name — this is a branded generic. It competes on the prescription market against other manufacturers' branded versions of the same molecule, as well as against INN-labelled generics.

Branded generics are dominant in India's retail pharmacy market for several reasons: - Prescribing habits oriented toward brand names, even for off-patent molecules - Brand as a quality signal in a market where quality differentiation between manufacturers is real - Pharmaceutical company investment in building prescriber relationships around their brand portfolio

For wholesale buyers, branded generics offer a combination of defined brand identity and generic price points — an important market segment in India's export trade.

---

Market Data Context

India's pharmaceutical market — one of the world's largest by volume — is tracked by independent market research firms including IQVIA (formerly IMS Health). IQVIA publishes periodic reports on market size, growth rates, and product category performance, which are widely referenced in the pharmaceutical trade.

---

What This Means for Buyers

---